During his program on CNBC on February 28, Jim Cramer expressed frustration with the impact of earnings reports on market behavior, noting how they often prompt rash decisions by average investors. He criticized the short-term focus and lack of attention to nuance in news coverage of earnings. Cramer cited examples of Home Depot and Lowe's, highlighting how investors reacted hastily to headline news without considering the broader context provided in earnings calls.
Top Pharma Stocks to Buy Now
2021-10-15 • Updated
The stocks of the vaccine producers have gained a lot during 2021 due to the wide vaccination campaign around the world. Still, the Covid-19 pandemic is still not over as the virus is mutating and the scientists need to create new and new vaccines. What does it mean for traders? A great opportunity to invest in pharma stocks especially the ones engaged in the production of vaccines.
Moderna
Moderna has joined the S&P 500 index this year. It skyrocketed to almost $500 – the all-time high on this news, but then dropped back to $300 amid the broad market correction. Moderna has recently submitted its COVID-19 booster shots for adults to the FDA. If officials approve it, the stock price of Moderna will rocket! The first resistance level lies at the round number of $350.00. If the stock manages to cross it, the stock may jump above the 50-day moving average at $400.00. Support levels are $295.00 and $250.00.
AstraZeneca
Many hedge funds have added AstraZeneca into their portfolios. Among them are Fisher Asset Management, GQG Partners, and other heavyweights. Apart from producing vaccines against Covid-19, the company produces other medicines and also working on an advanced breast cancer treatment. The key level of $8750 acts now as support, while it was acting like resistance during August. Thus, we might expect the price to retrace to this level and then reverse up to $9000. When AstraZeneca breaks above this level, it will rally up to $9250.
Johnson & Johnson
JNJ sells pharmaceuticals, consumer health products, and many well-known consumer goods (Johnson's Baby products, Acuvue contact lenses, etc). Apart from that, it’s a vaccine maker and quite a successful one! The FDA claimed that the second dose of the JNJ Covid -19 vaccine is effective two months after the first. As a result, the JNJ stock skyrocketed.
The stock of JNJ has failed to cross the psychological level of $160.00. If it manages to break it and the high of October 7 at $162.00, we might expect the downtrend to change to an uptrend. So far, the stock price is moving in the descending channel. Still, if we look at the weekly or monthly chart, we’ll see that it’s just a correction in the long-term uptrend. Thus, wait for the confirmation of the change of a trend.
Don't know how to trade stocks? Here are some simple steps.
- First of all, be sure you’ve downloaded FBS Trader app or Metatrader 5. FBS allows you to trade stocks only through this software.
- Open an account in FBS Trader or the MT5 account in your personal area.
- Start trading!
Similar
As the year winds down and the festive spirit takes hold, the stock market often presents a curious yet anticipated phenomenon known as the Santa Rally. Within this whirlwind of festive trading, let’s look at how two titans of the tech world, Amazon and Apple, might fare during this unique season.
Global equities on Wall Street experienced a mixed session following the Thanksgiving holiday, heading for the most significant one-month rally since November 2020. MSCI's global shares index slightly eased but was still on track for an 8.5% monthly gain, fueled by growing investor confidence that U.S. interest rates...
Latest news
The Reserve Bank of Australia (RBA) is widely anticipated to maintain its current interest rates at 4.35% following its two-day meeting concluding on Tuesday. Despite holding rates steady since December, the RBA has hinted at the possibility of further rate hikes due to persistently high inflation, which has exceeded its target range of 2% to 3%.
Coinbase (#COIN) saw its revenue rise to $773 million in Q1 2024, marking a 23% increase from the previous quarter and surpassing analyst expectations.
Bearish scenario: Sales below 80.00 with TP1: 79.60... Anticipated bullish scenario: Intraday purchases above 80.70 with TP: 81.50...